FDA defends increased use of guidance in new report to Congress

The FDA is de­fend­ing its in­creased use of non-bind­ing guid­ance doc­u­ments rather than legal­ly-en­force­able rule­mak­ings, ar­gu­ing that guid­ance can bet­ter keep pace with the lat­est …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.